REMODULIN

REMODULIN Basic information
Product Name:REMODULIN
Synonyms:2-[[[(1R,2R,3aS,9aS)-2α-Hydroxy-1β-[(S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-benzo[f]indene]-5-yl]oxy]acetic acid;UT-15;[[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-Hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic acid;Treprostinil-13C2-d1;Treprostinil free acid;BW 15AU;BW 15AU;LRX 15;RUMODOLIN;U-62840;UNIPROST;LRX 15
CAS:81846-19-7
MF:C23H34O5
MW:390.51
EINECS:808-233-7
Product Categories:Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:81846-19-7.mol
REMODULIN Structure
REMODULIN Chemical Properties
Melting point 121-123°
Boiling point 587.1±50.0 °C(Predicted)
density 1.158±0.06 g/cm3(Predicted)
storage temp. Sealed in dry,Store in freezer, under -20°C
solubility Chloroform (Slightly, Heated), Methanol (Slightly, Heated)
pka3.19±0.10(Predicted)
form Solid
color Off-White to Beige
Safety Information
MSDS Information
REMODULIN Usage And Synthesis
UsesSynthetic analog of Prostacyclin (P839060). Antihypertensive. Treprostinil, marketed under the trade name Remodulin is a medication used to treat pulmonary arterial hypertension (PAH).
DefinitionChEBI: Treprostinil is a carboxylic acid and a carbotricyclic compound. It has a role as a platelet aggregation inhibitor, a vasodilator agent, an antihypertensive agent, a cardiovascular drug, a vitamin K antagonist and a human blood serum metabolite.
PharmacokineticsTreprostinil is rapidly absorbed from the subcutaneous site of infusion, with an almost 100% bioavailability and a mean half-life of 85 minutes (34 minutes for the IV infusion). The IV solution must be diluted with normal saline or sterile water before starting the infusion. Unlike epoprostenol, treprostinil is stable at room temperature for up to 5 years, with vasodilation action lasting from 4 to 6 hours, compared with the short, 2- to 3-minute action for epoprostenol. Because of its long life in the body, it can be administered under the skin with a microinfusion subcutaneous infusion pump rather than into the bloodstream and, thus, without hospitalization, as contrasted with the central IV infusion of epoprostenol.
Clinical UseTreprostinil is a synthetic, stable form of prostacyclin for the treatment for advanced pulmonary hypertension with NYHA class III or IV symptoms as well as for late-stage peripheral vascular disease (PVD). Its sodium salt injectable form is administered either as a continuous subcutaneous infusion directly into the skin or, if the subcutaneous infusion is not tolerated, as a continuous IV infusion without an implanted catheter.
Side effectsSide effects include jaw pain, headaches, nausea, diarrhea, flushing, and localized pain at the delivery site under the skin. This pain has been reported as slight to severe irritation. Patients using the drug seem to ex-perience improvement in their condition, including decreased fatigue, decreased shortness of breath, and decreased pulmonary artery pressures, as well as overall improvement in quality of life.
storageStore at -20°C
(R*,R*)-N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide fumarate dihydrate Albendazole Sofosbuvir Mecobalamin Latanoprost Sildenafil Epoprostenol REMODULIN Voglibose Travoprost Prostaglandin E1 Ziprasidone Atracurium besylate Fenofibrate Bortezomib Beraprost REMODULIN Phenoxyacetic acid sodium salt

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.